Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
    • CHEST 2021
    • IDWeek 2021
    • IAS 2021
    • ADA 2021
    • ATS 2021
    • ACC 2021
    • ACP 2021
    • AAN 2021
Current Drug Therapy

Labetalol and other agents that block both alpha- and beta-adrenergic receptors

Donald G. Vidt, MD, Alan Bakst, PharmD, Carolyn J. Pearce, MD and J. David Wallin, MD
Cleveland Clinic Journal of Medicine January 1994, 61 (1) 59-69;
Donald G. Vidt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alan Bakst
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolyn J. Pearce
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J. David Wallin
Department of Medicine, Section of Nephrology, Louisiana State University School of Medicine, New Orleans.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
  • PDF
Loading

ABSTRACT

BACKGROUND Labetalol, a compound that blocks both alphaand beta-adrenergic receptors, is the only drug of its class currently available in the United States.

OBJECTIVE To review the pharmacology of labetalol and related compounds.

SUMMARY Unlike "pure" beta blockers, labetalol maintains cardiac output, reduces total peripheral resistance, and does not decrease peripheral blood flow. It has been used to treat hypertension of all degrees of severity and may be especially useful in black patients, elderly patients, patients with renal disease, and in pregnancy. It can be used in conditions that produce catecholamine crises, such as pheochromocytoma, clonidine withdrawal, and cocaine overdose. Its hemodynamic profile is attractive for use in myocardial ischemia. The parenteral form is useful in situations where blood pressure must be lowered quickly. The major side effect is orthostatic hypotension, and hepatotoxicity has been reported.

CONCLUSIONS Labetalol has several advantages over pure beta-blocking drugs and offers an alternative in managing hypertension that is difficult to control.

INDEX TERMS
  • Labetalol
  • Adrenergic Alpha Receptor Blockaders
  • Adrenergic Beta Receptor Blockaders
  • Copyright © 1994 The Cleveland Clinic Foundation. All Rights Reserved.
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 61 (1)
Cleveland Clinic Journal of Medicine
Vol. 61, Issue 1
1 Jan 1994
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Labetalol and other agents that block both alpha- and beta-adrenergic receptors
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Labetalol and other agents that block both alpha- and beta-adrenergic receptors
Donald G. Vidt, Alan Bakst, Carolyn J. Pearce, J. David Wallin
Cleveland Clinic Journal of Medicine Jan 1994, 61 (1) 59-69;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Labetalol and other agents that block both alpha- and beta-adrenergic receptors
Donald G. Vidt, Alan Bakst, Carolyn J. Pearce, J. David Wallin
Cleveland Clinic Journal of Medicine Jan 1994, 61 (1) 59-69;
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Update on current contraceptive options: A case-based discussion of efficacy, eligibility, and use
  • Antiobesity drug therapy: An individualized and comprehensive approach
  • The role of SGLT-2 inhibitors in managing type 2 diabetes
Show more Current Drug Therapy

Similar Articles

Keywords

  • Labetalol
  • Adrenergic Alpha Receptor Blockaders
  • ADRENERGIC BETA RECEPTOR BLOCKADERS

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2023 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire